Podcasts about Precision medicine

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most effective way to drive change in healthcare is to focus on what remains constant: serving patients. In this episode, sponsored by Amgen. Leandro Boer, Vice President of US Medical and General Medicines at Amgen, discusses how the company is reimagining care delivery to enhance access and outcomes, particularly for underserved populations. He explains how precision medicine, multi-omics, and advanced data use are driving innovation and preventing “data waste,” while Amgen invests heavily in R&D, including a $600 million Innovation and Discovery Science Center. Leandro highlights the role of technology in accelerating clinical trials through machine learning and anticipates three major shifts within the next five years: faster drug development, reduced administrative burden through the use of AI, and improved patient identification via care pathway automation. He also highlights Amgen's goal to reduce cardiovascular events by 50% by 2030, the importance of diverse clinical representation through the RISE initiative, and the company's commitment to employee well-being as the foundation for improved patient care. Tune in and learn how innovation, equity, and purpose-driven leadership are transforming the future of healthcare! Resources: Connect with and follow Leandro Boer on LinkedIn. Follow Amgen on LinkedIn and explore their website.

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About Leandro Boer:Leandro Boer, MD, PhD, is a seasoned global biopharmaceutical executive and physician specializing in cardiology and cardiovascular pharmacology. Currently serving as Vice President of US Medical, General Medicines at Amgen, he leads medical strategy and execution across cardiovascular, bone, neuroscience, nephrology, and obesity therapeutic areas, overseeing a nationwide organization of over 100 professionals. With more than two decades of experience spanning the United States, Latin America, Canada, Africa, and the Middle East, Dr. Boer has built a distinguished career at leading companies such as Amgen, AstraZeneca, and Novartis.His leadership has shaped global and regional initiatives in medical affairs, clinical development, real-world evidence generation, regulatory strategy, and implementation science. Clinically, his expertise covers resistant hypertension, type 2 diabetes, obesity, heart failure, chronic kidney disease, and hyperlipidemia. Known for combining scientific rigor with strategic vision, Dr. Boer has directed cross-functional teams supporting drug development, commercialization, and lifecycle management across multiple therapeutic areas.A medical doctor trained in cardiology with a Ph.D. in cardiovascular pharmacology from Universidade Estadual de Campinas, Dr. Boer has consistently demonstrated a commitment to advancing evidence-based medicine, patient outcomes, and collaborative leadership within the healthcare ecosystem.Things You'll Learn:The foundation of innovation lies in focusing on what never changes—patients, healthcare providers, and equitable systems of care.Amgen's precision medicine and data-driven strategies prevent “data waste” and ensure every insight contributes to patient outcomes.Machine learning tools like Atomic are accelerating clinical trials by predicting successful sites, leading to faster drug development.The company's bold goal to reduce cardiovascular events by 50% by 2030 relies on partnerships, AI, and implementation science.Representation in clinical research and decentralized trials is crucial to ensuring equitable access and meaningful outcomes for all populations.Resources:Connect with and follow Leandro Boer on LinkedIn.Follow Amgen on LinkedIn and explore their website.

In this episode of the Eye on AI Podcast, Craig Smith sits down with Steve Brown, founder of CureWise, to explore how agentic AI is reshaping healthcare from the patient's perspective. Steve shares the deeply personal story behind CureWise, born out of his own experience with a rare cancer diagnosis that was repeatedly missed by traditional medical pathways. The conversation dives into why modern healthcare struggles with complex, edge-case conditions, how fragmented medical data and time-constrained systems fail patients, and where AI can meaningfully help without replacing clinicians. The discussion goes deep into multi-agent AI systems, reliability through consensus, large context windows, and how AI can surface better questions rather than premature answers. Steve explains why patient education is the real unlock for better outcomes, how precision medicine depends on individualized data and genetics, and why empowering patients leads to stronger collaboration with doctors. This episode offers a grounded, practical look at AI's role in healthcare, not as a diagnostic shortcut, but as a tool for clarity, context, and better decision-making in some of the most critical moments of car   Stay Updated: Craig Smith on X: https://x.com/craigssEye on A.I. on X: https://x.com/EyeOn_AI (00:00) Using Multi-Agent AI to Analyze Medical Records (04:35) Steve Brown's Tech Background and Return to Healthcare (08:25) How a Rare Cancer Diagnosis Was Initially Missed (13:55) Why Modern Medicine Struggles With Complex Cases (18:29) Multi-Agent Consensus and AI Reliability in Healthcare (24:12) Large Context Windows, RAG, and Medical Data Organization (28:24) Why CureWise Focuses on Patient Education, Not Diagnosis (33:10) Precision Medicine, Genetics, and Personalized Treatment (47:45) Why CureWise Launches Direct-to-Patient First (53:19) The Future of AI-Driven Precision Medicine

What if the missing link in treating autoimmune disease wasn't a new drug—but a better way to measure stress? In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision .At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease. Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions. Whether you're a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation.

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Wei-Wu, Executive Chairman at Human Longevity, Inc. Together, they explore how advances in genome sequencing, AI, and multi-layered diagnostics are changing the fight against age-related diseases. Wei-Wu shares why understanding your own genetic risks and combining them with other health data leads to better prevention and a longer healthspan.Wei-Wu explains the value of integrating genome sequencing, advanced imaging, and liquid biopsy to catch diseases like cancer early, before symptoms appear. He draws on real-world examples, including how combining different tests can spot cancers that single methods might miss. The conversation highlights how technology brings down costs, making once-rare insights widely available, and how each person stands to benefit from personalized risk profiles.The episode closes with practical advice: use today's tools to become the CEO of your own health. Wei-Wu urges listeners to embrace data-driven, individualized care and stresses that no single tool or habit holds all the answers. Instead, true longevity comes from a holistic, ongoing approach, one that uses all available knowledge to prevent disease and extend both life and health.Guest-at-a-Glance

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this follow-up conversation with Dr. Anil Bajnath, MD, Debi Robinson explores how precision medicine can be used not to “bio-hack” the body, but to bio-harmonize it — restoring balance, resilience, and clarity in the bone health journey.Rather than relying on one-size-fits-all recommendations or waiting for disease to show up on a DEXA scan, this episode focuses on understanding the body's internal signals earlier. Dr. Bajnath explains how stress, gut health, blood sugar regulation, sleep quality, and recovery capacity directly influence bone remodeling and long-term fracture risk.This episode is especially empowering for women who feel overwhelmed by conflicting advice and want a calmer, more intelligent path to supporting their bones.What You'll Learn in This EpisodeThe difference between bio-hacking and bio-harmonizing your healthWhy stress can override even the best nutrition and exercise planHow gut health and blood sugar regulation affect bone strengthWhat wearables and continuous glucose monitors (CGMs) reveal about inflammation and recoveryWhy sleep quality is a critical bone-building factorHow inflammation quietly accelerates bone lossWhy balance and awareness matter more than extremesAction Steps You Can Take TodayPrioritize sleep — this is when bone repair and cellular regeneration occur.Reduce inflammatory foods temporarily to calm the immune system.Support digestion first before adding more supplements.Manage stress daily through breathwork, yoga, or gentle movement.Use data tools wisely — short-term tracking for insight, not obsession.Choose balance over extremes in exercise, nutrition, and lifestyle.Resources & Linkshttps://debirobinson.com/stronger-bones-lifestyle-podcast-take-control-of-your-bone-health/Healthy Gut, Healthy Bones Program: https://debirobinsonwellness.thrivecart.com/hghb-self-paced-group-program-pp/Learn More About Dr Bajnathhttps://anilbajnath.com/Debi's TakeawayBone health isn't about chasing perfection or controlling every variable. It's about restoring harmony — supporting digestion, calming stress, improving sleep, and listening to your body's signals.Precision medicine gives us clarity, but awareness and lifestyle give us power. When we bio-harmonize the body instead of fighting it, bones respond.

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

In this episode, Debi Robinson sits down with Dr. Anil Bajnath, MD, a board-certified physician and leader in precision medicine, to explore how personalized healthcare is reshaping the future of bone health and osteoporosis prevention.Rather than waiting for bone loss to appear on a DEXA scan, precision medicine focuses on identifying the root biological drivers of bone loss years earlier—chronic inflammation, mitochondrial decline, hormonal imbalance, gut dysfunction, immune aging, and cellular senescence.This conversation offers a hopeful, empowering reframe: bone loss is not an inevitable consequence of aging, but a reflection of modifiable biological processes. When we understand and support those processes early, we create the conditions for stronger bones, healthier aging, and greater resilience.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant events of 2025, a year marked by pivotal scientific breakthroughs, regulatory changes, and industry trends that have reshaped drug development and patient care.One of the standout advancements was Novo Nordisk gaining FDA approval for an oral version of Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist for obesity management. This marks a notable shift in treatment accessibility, as it provides an easier alternative to injectables for those managing weight and cardiovascular risks. This development could significantly enhance patient adherence and broaden access to this critical therapy.However, not all news was positive. Pfizer faced a challenging situation when a patient death occurred in the extension of their Hympavzi hemophilia study. Such incidents highlight the intrinsic risks of clinical trials, especially within gene therapy realms where safety monitoring is paramount. These events remind us of the delicate balance between innovation and patient safety in advanced biologic therapies.In legal news, Johnson & Johnson was ordered by a Baltimore jury to pay $1.56 billion in a talc-related cancer case. This ruling underscores heightened scrutiny on product safety and consumer protection within the pharmaceutical industry, potentially influencing future litigation and regulatory measures.Clinical trial outcomes also presented mixed results. Neurocrine Biosciences' Ingrezza did not meet efficacy endpoints in its phase 3 trial for cerebral palsy-related dyskinesia. Although it is approved for other movement disorders, this setback reflects the complexities involved in expanding drug indications. Such challenges highlight ongoing hurdles in translating preclinical successes into clinical realities.Despite geopolitical tensions, particularly between China and the U.S., Chinese biotech firms thrived, maintaining robust deal activity. China's continued growth as an innovation hub is driven by strategic investments and collaborations that bolster global drug development efforts, underscoring its increasing influence in life sciences.Regulatory landscapes also shifted with proposals from the Center for Medicare & Medicaid Innovation to align U.S. drug prices with international rates under Medicare Parts B and D. These proposed models could significantly impact pricing strategies and market dynamics within the U.S., requiring pharmaceutical companies to adapt while ensuring equitable access to medications.Ethical challenges surfaced as six individuals were charged with insider trading involving biotech stocks. Such incidents highlight the necessity for stringent ethical standards and regulatory oversight to maintain investor confidence and market integrity.Meanwhile, AstraZeneca's extended partnership with Niowave for actinium-225 supply reflects an interest in radiopharmaceuticals as targeted cancer therapies. This collaboration highlights the potential of radiopharmaceuticals in oncology, opening promising avenues for precision medicine approaches.As 2025 closes, it's clear that this year has been one of both triumphs and trials for the pharmaceutical and biotech industries. Scientific innovations like Novo Nordisk's oral GLP-1 receptor agonist offer new hope for patients, yet challenges such as clinical trial setbacks and legal battles indicate ongoing hurdles in drug development and commercialization. These developments will likely influence industry strategies and regulatory policies as we advance into 2026.The sustained momentum of China's biotech industry amid global trade tensions remains notable. This trend reflects China's strategic investments in biotech capabilities and its growing role in global markets despite geopolitical frictions.In clinical research, Hope BioscienceSupport the show

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Maximizing your healthspan requires understanding your specific genetic blueprint to see how your body processes fats, carbs, and antioxidants. Standard medical school training provides only a fraction of the education needed to understand nutrition and prevention. I sat down with Dr. Jeff Graham to uncover why common health "hacks" like Vitamin E or intermittent fasting might be backfiring based on your DNA. We explore the transition from high-intensity athletics to longevity-focused movement, and how advanced testing identifies disease risks years before they appear on a standard lab report.Jeff breaks down the impact of the APOE and MTHFR genes on brain health, the surprising anti-inflammatory benefits of sardines, and why muscle mass is your greatest currency as you age. We also discuss the future of AI in diagnostics, the truth about CrossFit injuries, and why contrast therapy is a non-negotiable for cellular resilience."If you're investing in anything with your time or your money that isn't asking you to do something hard most days, then you need to run away." - Dr. Jeff GrahamSupport the show and get 50% off MCT oil with free shipping—just leave us a review on iTunes and let us know!https://podcasts.apple.com/us/podcast/live-beyond-the-norms/id1714886566 About Jeff Graham:Dr. Jeff Graham is a performance and longevity expert combining clinical expertise with precision genomic medicine. He holds a medical degree from the University of Arkansas, completed his residency in North Carolina, and graduated cum laude from a sports medicine fellowship with board certification in lifestyle medicine. As Chief Medical Officer at Wild Health, Jeff focuses on leveraging advanced testing and data-driven insights to maximize health spans for clients ranging from senior executives to competitive CrossFit athletes.Connect with Jeff Graham:- Website: https://wildhealth.com - Instagram: https://www.instagram.com/wildhealthmd/ - LinkedIn: https://www.linkedin.com/in/precisionmdjeff/ Connect with Chris Burres:- Website: https://www.myvitalc.com/ - Website: http://www.livebeyondthenorms.com/ - Instagram: https://www.instagram.com/chrisburres/ - TikTok: https://www.tiktok.com/@myvitalc - LinkedIn: https://www.linkedin.com/in/chrisburres/ DisclaimerThe content shared in this podcast is intended for educational and informational purposes only. It does not constitute medical advice of any kind, nor does it include any specific claims or guarantees. The views expressed are based on personal experiences, research, and individual perspectives, and are meant to inspire and inform listeners on topics related to wellness, lifestyle, and personal development.We strongly encourage all listeners to consult with a qualified professional or licensed expert before making any decisions related to health, finances, or other sensitive areas of life. Thank you for tuning in—and for taking proactive steps toward a more informed, intentional life.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest translational insights into resistance mechanisms, including genomic alterations affecting cell cycle and signal transduction pathways, and discusses evolving therapeutic strategies. Dr. Wander is an Assistant Professor of Medicine at Harvard Medical School and the Director of Precision Medicine at the Termeer Center for Targeted Therapies at Mass General Brigham Cancer Institute. He also spoke about this topic at the 2025 San Antonio Breast Cancer Symposium.

Drs. Adegunsoye and Kaul review their takeaways from CHEST 2025, where pulmonary experts revealed a transformative approach to interstitial lung disease that emphasizes precision medicine and personalized treatments. The conference marked a shift from passive observation to proactive intervention, focusing on early screening, targeted therapies, and reducing healthcare disparities.

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is my 200th episode and I reflect on where medicine is at in terms of precision medicine and what it means for us.Links:Please take this 10 minute survey to help keep this podcast going: http://bit.ly/savinglivesinslowmotion-surveyGenome sequencing: https://www.genomicsengland.co.uk/blog/what-happens-when-i-go-for-whole-genome-sequencingMepan Syndrome: https://umdf.org/mepan/Ketones in dementia: https://pmc.ncbi.nlm.nih.gov/articles/PMC8734638/London Bus study: https://cardiachealth.org.uk/the-london-busmen-study/Drumming - physical and mental therapy?: https://melodics.com/blog/mental-health-benefits-of-drummingSave your life in slow motion and those of others by subscribing now and sharing. Thank you for listening and for your support. It means a lot to me. Hosted on Acast. See acast.com/privacy for more information.

Everyone touched by cancer knows treatments vary depending on the type of cancer. Now, with precision medicine for some cancers, treatments can be tailored to that cancer. In this podcast, Dr. James Hamrick, MD, MPH, explains what precision medicine means for cancer patients and updates listeners on developments in testicular cancer treatments. Dr. Hamrick is the chairman of the Caris Precision Oncology Alliance, known as Caris POA at Caris Life Sciences. He leads a global network of top cancer centers and research institutions dedicated to advancing precision oncology and biomarker-driven research, and he will tell us all about it. Dr. Hamrick is board-certified in internal medicine, medical oncology, and hematology. He earned his MD and MPH in epidemiology from the University of North Carolina and completed his residency and fellowship at the University of California, San Francisco.Now - back to precision medicine. Here's what Dr. Hamrick explains in the podcast.00:09:55"When we treat a cancer, it's all about hitting the cancer, the bad part, and not hurting the rest of the person. And so the more we understand the targets we should be hitting in these tumors, the better we can design treatments that hit those targets and leave the rest of the cells in a person's body alone."What does that mean? "It means fewer side effects, so more effectiveness. So when you hear precision medicine, think about this: this is where my doctor is not just treating me for cancer. Not just treating me for lung cancer, but is working to understand exactly what is driving my cancer and how can we best target that so I have the best outcome, meaning we can kill those cancer cells, right?"And the fewest side effects. That's really precision oncology. Biomarkers bio. We all know from high school biology class that the life sciences markers are the targets. So these are the targets that we can now use at Caris and other vendors. We can say, hey, that's the problem here."It's not just one testicular cell that went bad; it's one that has this certain molecular profile. So I tell patients: You should ask your doctors, Hey, what biomarkers do we care about? What is important? What are we targeting? What's valuable here?"And that's part of becoming fluent in the language of your cancer, which, as many caregivers know, is really important."Dr. Hamrick talks more about testicular cancer and the need to find genetic biomarkers for it. He explains that and related research about testicular and other types of cancer in this episode of Don't Give Up on Testicular Cancer from the Max Mallory Foundation. Links:Caris Precision Oncology Alliance - Caris POAhttps://www.carislifesciences.com/partners/caris-precision-oncology-alliance/James Hamrick, MD, MPHhttps://www.carislifesciences.com/bio/james-hamrick-md-mph/Max Mallory Foundationhttps://www.maxmalloryfoundation.comDon't Give Up on Testicular CanceSend us a textSupport the showFind us on Twitter, Instagram, Facebook & Linkedin. If you can please support our nonprofit through Patreon.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if your lab work, genetics, and lifestyle data could all talk to each other—giving you a single, clear picture of how to optimize your energy, hormones, and longevity? In this episode, I sit down with Dr. Meghan Jones, a board-certified Emergency Medicine physician and Fellow of Wild Health's Precision Medicine Program, to explore how their Clarity Report™ uses genomics and biomarker analysis to map out a personalized path toward healing and performance. Dr. Jones shares her journey from emergency medicine to precision health—why she left crisis care to help people prevent disease and live stronger, longer lives. Together we unpack my own Wild Health Clarity Report™ findings and discuss how data-driven coaching can uncover the hidden stressors, nutrient gaps, and hormone imbalances that keep you stuck. In this episode: What the Wild Health Clarity Report™ measures and why it matters How genetics, labs, and lifestyle data combine to reveal your root causes My personal insights from metabolic and hormone testing How precision medicine can improve energy, resilience, and longevity If you're ready to move beyond symptom management and start your own investigation, visit www.wildhealth.com and use code COACHDEBBIEPOTTS to save on your Precision Medicine Clarity Report™. Guest Bio: Dr. Meghan Jones, MD is a board-certified Emergency Medicine physician and Fellow of Wild Health's Precision Medicine Program. She earned her medical degree at West Virginia University and completed her residency at The Ohio State University. After years in emergency medicine, Dr. Jones transitioned to precision health to help patients uncover root causes and achieve results once thought out of reach. She's passionate about helping people live as well as they can—for as long as they can—and is an active mom of two who loves fitness, outdoor adventure, and community. Links

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and challenges that are shaping this dynamic industry.Pfizer has recently unveiled phase 3 results for its hemophilia drug Hympavzi, positioning it as a formidable competitor against Sanofi's Qfitlia and Novo Nordisk's Alhemo. The data suggests Hympavzi offers robust efficacy, potentially revolutionizing hemophilia treatment and enhancing patient outcomes significantly. This development is not just about competition; it represents a critical stride forward in patient care for those affected by this debilitating condition.UCB plans to seek regulatory approval for Fintepla to treat an additional epileptic disorder following positive phase 3 trial results in patients with CDKL5 deficiency disorder. This decision reflects promising results and could offer new hope to patients with limited treatment options, further cementing Fintepla's position in epilepsy management.Gene therapy continues to shine with CSL's Hemgenix demonstrating sustained long-term benefits. After five years of follow-up, a single dose has reduced annualized bleeding rates by an impressive 90% in hemophilia B patients within the Hope-B study. Such long-term efficacy highlights gene therapy's transformative potential, offering lasting improvements in quality of life for patients with genetic disorders.Regulatory frameworks are also evolving, as evidenced by the CDC's Advisory Committee on Immunization Practices (ACIP) voting to modify hepatitis B vaccine guidance for newborns. This decision advocates an individualized approach, sparking debate over vaccination strategies, which reflects the complexities and delicate balance required in public health policies today.Regeneron is making strides to simplify treatment regimens for T-cell engagers Lynozyfic and Ordspono. By reducing regimen complexity, they aim to improve patient compliance and expand access, thus enhancing the potential impact on cancer care—a crucial step toward broader therapeutic accessibility.In an effort to address cost barriers and stimulate domestic production of generics, Mark Cuban has proposed lowering FDA fees. This proposal highlights ongoing discussions around regulatory reforms needed to boost generics manufacturing in the United States. Such initiatives align with broader industry goals of increasing access to affordable medications.Despite these advancements, industry insiders have expressed concerns about "unprecedented turmoil" within the FDA. These challenges underscore the critical role of stable leadership in maintaining public trust and ensuring effective regulation amidst rapid scientific progress.Obesity treatments are gaining significant attention as companies like Wave Life Sciences and Structure Therapeutics report promising data, capturing increased investor interest. This trend underscores a growing focus on innovative pharmacological approaches to address obesity—a complex, multifactorial condition that affects millions globally.The strategic landscape of cancer diagnostics is also evolving, as evidenced by Natera's acquisition of Foresight Diagnostics. This deal underscores ongoing industry consolidation efforts aimed at enhancing technological capabilities and expanding market presence—a testament to the critical role diagnostics play in comprehensive cancer care strategies.As we observe these developments, it's clear that scientific innovation coupled with strategic regulatory maneuvers is shaping the future of healthcare. These advancements offer profound implications for patient care, providing new hope through advanced therapies while highlighting the importance of effective regulation and strategic partnerships.Precision medicine continues to extend beyond oncology into fields like cardiometabolic and neSupport the show

The 2025 Medical Innovation Olympics featured one of the most memorable and personal interviews with Amber Salzman, CEO at Epicrispr Biotechnologies, an extraordinary leader with unparalleled sense of purpose, urgency, PhD in mathematics and illustrious track record of success as a pharmaceutical industry executive with over 30 years of experience that included growing revenue, shareholder value, and accelerating innovative treatments. She began her career leading R & D at GSK with a clinical pipeline responsibility for $1.25 billion, prior to serving as CEO at Cardiokine, CEO at Avalanche, co-founder of Annapurna, SAS, CEO of Adverum, Ohana Biosciences. She currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing.In this interview Amber speaks about her personal and family's struggle with neurodegenerative rare diseases and the critical new discoveries in gene regulation to switch genes on and off rather than cut DNA which she has guided and accelerated with the support of an extraordinary team of Nobel Prize laureates and scientists at Epicrispr. 0:00 - Highlight 1 - Amber's Family's Personal Struggle with Rare Neurodegenerative Disease1:02 - Highlight 2 - Patient's Real-World Story from the 9/11 tragedy2:31 - Highlight 3 - Vision & Stamina Needed to Address Unpredictability of Human Biology 4:03 - Speaker Introduction7:19 - Keys to Transition from R & D to CEO/Commercial Leader10:22 - Approach to decision-making as a leader with urgency & purpose14:00 - Epigenetic Editing and How it is different from CRISPR16:36 - Challenges on the journey to Epicrispr's discovery18:14 - Second challenge - finding a gene modulator with which to fuse it 18:49 - Patients vary significantly in how they express their symptoms19:52 - Springbuck Analytics Partnership - Whole Body Imaging21:14 - Recent disappointments from Sarepta in Duchenne's muscular dystrophy25:48 - How Amber's personal family experiences with Genetic Diseases impacted her leadership journey29:47 - When could FSHD patients finally access this new treatment?31:27 - What other disease conditions is Epicrispr considering in its development program?33:27 - Amber's Lessons: Stay focused on patients, learn, and co-develop treatments together

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Advances in molecular diagnostics are reshaping how cancer is detected, monitored, and treated, and liquid biopsy is becoming central to that progress. This simple blood draw can reveal key tumor biology at diagnosis and over time, providing timely insight and guiding more precise decisions throughout a patient's journey. Clinicians now face an important challenge: knowing what is actionable today and what is coming next so more patients can benefit from the promise of these advances.As we kick off Season 7, host and patient advocate Karan Cushman expands this season's focus on Bringing Precision Medicine to Everyone with a deeper look inside the science of liquid biopsy. The conversation features two leaders shaping the field: Dr. Christian Rolfo, Division Director of Medical Oncology at The James Comprehensive Cancer Center at Ohio State University, and Dr. Roberto Borea, Medical Oncologist and emerging investigator from the Rolfo Lab.Together, they break down the scientific momentum driving liquid biopsy forward, including tumor fraction, MRD-guided treatment strategies, resistance monitoring, fragmentomics, and the expanding frontier of early detection. They also discuss the barriers that continue to slow broader adoption, such as assay variability, limited standardization, reimbursement gaps, and operational challenges in community settings.In this episode, we cover:• How tumor fraction is emerging as a meaningful real-time biomarker• Where MRD-driven escalation and de-escalation strategies are heading• The current promise and limitations of early detection and MCED testing• What is required to standardize liquid biopsy across reporting, workflows, and clinical trialsEpisode 70 offers a clear look at the advances researchers are helping drive right now and what these developments could mean for clinicians, laboratories, and patients in the near future.This conversation builds on episode 69 with Dr. Kashyap Patel, who introduced the foundations of liquid biopsy and its role in accelerating treatment decisions. Combined, these two episodes offer clinicians and patients an overview of where the science and real-world applications stand now and where the field is headed next.

In a rapidly evolving healthcare landscape, the intersection of technology and medicine is paving the way for groundbreaking advancements. Join us for a conversation with Dr. Jessica Mega, a Cardiologist at Stanford and a pioneer in precision health. Dr. Mega shares her insights on the transformative potential of precision medicine and artificial intelligence in diagnostics, as well as the challenges that lie ahead. Discover how interdisciplinary collaboration among engineers, data scientists, and clinicians is driving innovation, and learn about the vital role of precision medicine in preventive care and population health. With a focus on preparing the next generation of clinicians, Dr. Mega offers guiding principles for fostering innovation in health technology. Read Transcript: https://mcdn.podbean.com/mf/web/syejzt9pgskrrn54/medcast_episode113.pdf CME Information: https://stanford.cloud-cme.com/medcastepisode113 Claim CE and MOC: https://stanford.cloud-cme.com/Form.aspx?FormID=3685  

Chronic obstructive pulmonary disease (COPD) care is evolving—learn how communication and patient empowerment are transforming treatment. Credit available for this activity expires: 11/28/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/patients-progressing-ai-cdk4-6-inhibitors-biomarkers-2025a1000wtp?ecd=bdc_podcast_libsyn_mscpedu

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode, host Fred Goldstein invites Daryl Pritchard, Senior Vice President of Science Policy at the Personalized Medicine Coalition. They discuss how precision medicine is transforming care and where critical gaps remain. Daryl shares findings from recent studies showing how many patients are still lost along the testing-to-treatment pathway, even in well-established areas like lung cancer, and explains what's needed to bridge those gaps. The conversation highlights the role of payers, providers, and policymakers in aligning science, practice, and policy to deliver truly individualized care. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

AI in Healthcare: Who Benefits, Who Pays, and Who's at Risk in Our Hybrid Analog Digital Society

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden interviews Dr. Michael Renzulli, who shares his journey into healthcare, transitioning from traditional practices to holistic approaches. They discuss the emergence of red light therapy, its scientific basis, and its applications in treating various health issues, particularly obesity and metabolic health. The conversation emphasizes the importance of innovative healing technologies and their potential to transform lives. In this conversation, Dr. Jeffrey Gladden and Dr. Mike Renzulli explore the evolution of healthcare from merely managing symptoms to addressing root causes through precision medicine. They discuss innovative approaches to weight loss, the importance of detoxification, and the role of GLP-1 medications. The conversation emphasizes the significance of body composition over weight alone, the impact of fasting, and the necessity of a systems approach to health optimization, including thyroid function and oxidative stress management. Ultimately, they advocate for personalized solutions tailored to individual needs for lasting health improvements.   For Audience Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways         Dr. Renzulli's early inspiration for healthcare came from witnessing a life-saving moment.         His journey led him to explore holistic approaches after observing disillusionment in traditional doctors.         Red light therapy emerged as a significant tool in his practice, offering innovative health solutions.         The design and proximity of red light beds are crucial for effective treatment outcomes.         Different wavelengths of light have varying effects on the body, from skin rejuvenation to deeper tissue healing.         Red light therapy can enhance ATP production and reduce oxidative stress.         Integrating red light therapy with other treatments can improve metabolic health and energy levels.         Obesity is a growing epidemic, and red light therapy can play a role in weight loss.         The technology behind red light therapy is backed by numerous studies and evidence-based results.         Patients experience significant improvements in health and well-being through these innovative therapies. Patients are increasingly seeking root cause solutions rather than just symptom management.         Precision medicine offers real hope and tangible results for patients.         Weight loss strategies must focus on detoxification and cellular health.         Inflammation is a key factor in weight gain and insulin resistance.         A systematic approach to health can yield better outcomes than isolated treatments.         Body composition is a more important metric than weight alone.         GLP-1 medications can have adverse effects on muscle and bone density.         Fasting can be beneficial if done correctly, focusing on fat loss rather than muscle loss.         Precision medicine requires a deep understanding of individual genetics and biology.         A comprehensive approach to health includes monitoring thyroid function and metabolic rates.   Chapters 00:00 Introduction to Healthcare Journey 03:01 Transitioning from Traditional to Holistic Healthcare 06:12 The Rise of Red Light Therapy 08:56 Understanding Red Light Technology 11:52 The Science Behind Wavelengths and Healing 14:55 Applications of Red Light Therapy in Health 17:55 Addressing Obesity and Metabolic Health 20:50 Integrating Therapies for Optimal Health 23:45 The Shift from Symptom Management to Root Cause Healing 24:40 Real Results: The Promise of Precision Medicine 25:59 Innovative Approaches to Weight Loss and Wellness 28:50 The Science of Detoxification and Cellular Reset 31:05 Understanding Oxidative Stress and Inflammation 32:37 The Importance of Body Composition Over Weight 36:01 The Role of GLP-1 in Weight Management 38:34 Fasting and Its Impact on Body Composition 40:52 Precision Medicine: Tailoring Solutions for Individuals 42:07 Balancing Thyroid Function for Weight Loss 46:49 The Systems Approach to Health Optimization   To learn more about Dr. Renzulli: Email:  info@bioantiage.com Website: www.bioantiage.com   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today my guest is Dr Osama Khan from Natera What we discuss with Dr Khan : His journey into pathology The importance of mentorship in pathology Pathology at the intersection of diagnostics and precision medicine The collaborative nature of pathology Transitioning from academia to industry Natera and Cell-Free DNA Testing Understanding Circulating Tumor DNA (CtDNA) The role of MRD Testing in cancer treatment Personalized testing and tumor informed tests His thoughts on AI in pathology His advice for aspiring pathologists Links for this episode: InVision from Cision Vision The Path to PathA Pathologists' Assistant Shadowing Network Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Natera Osama Khan: The critical importance of embracing AI and digital workflows in medical practice   People of Pathology Podcast: Twitter Instagram

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC). --- This podcast is supported by: Ferring Pharmaceuticals https://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/ --- SYNPOSIS The conversation covers the current challenges of interpreting positive biomarkers without clinical correlates, the gold standard of biopsies, and the potential of various biomarkers such as urine cytology, FISH, and newer genomic tests like the Decipher Bladder Genomic Classifier. They also touch upon the role of AI in pathology, the cost implications of biomarkers, and how these tools might influence future clinical practices and patient decisions. The episode emphasizes the need for precision medicine, careful patient counseling, and the impact of false positives and negatives on both patients and healthcare providers. --- TIMESTAMPS 00:00 - Introduction05:25 - Challenges with Current Biomarkers08:10 - New Biomarkers and Genomic Classifiers21:10 - AI and Pathology in Bladder Cancer35:13 - Screening and Future Directions41:20 - Challenges and Future Directions in Bladder Cancer Surveillance57:51 - Conclusion --- RESOURCES DaBlaCa-15 Trialhttps://pubmed.ncbi.nlm.nih.gov/40280776/ Sam Chang CHAI Studyhttps://pubmed.ncbi.nlm.nih.gov/40514253/

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Fluoropyrimidines such as 5-fluorouracil (5-FU) and capecitabine remain cornerstone chemotherapies in oncology. However, for patients with certain DPYD gene variants, these commonly used drugs can cause life-threatening toxicities due to impaired metabolism of the active compounds. In this episode of the Precision Medicine Pharmacist Podcast, host Melissa Smith, PharmD, explores how DPYD genotyping is transforming oncology care by helping clinicians identify patients at risk before toxicity occurs. Joined by Karen Merritt, an advocate for universal DPD testing and leader with the Test4DPD initiative, the discussion sheds light on how pharmacogenomics is shaping safer, more personalized cancer treatment. Together, they explore current evidence, new FDA updates, and implementation frameworks that empower pharmacists and oncology teams to prevent preventable harm through precision medicine.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.